Latest Breaking News On - Anna ljung - Page 10 : comparemela.com

OncoZenge expands the board with Hilde Furberg Search jobs OncoZenge expands the board with Hilde Furberg OncoZenge AB (publ) (“OncoZenge”), Moberg Pharma AB (publ)’s subsidiary, has at an Extraordinary Shareholders Meeting today resolved on expanding the board with Hilde Furberg ahead of the listing on Nasdaq First North Growth Market, which is planned to take place during the first quarter of 2021. Hilde Furberg (born 1958) represents Linc AB and is an independent consultant and a professional board member. She has broad senior leadership experience, coming from her over 35 years in sales, marketing, strategy and general management roles in pharmaceuticals and biotechnology. Her experience is in different areas of specialty care, and from small to large global companies. Hilde has worked in companies like Baxter and Genzyme, and she was most recently the European Head of Rare Diseases for Sanofi Genzyme. Hilde has also been a board member of Pr

Hilde furbergAnna ljungMoberg pharmaSanofi genzymePirkko tamsenOslo universityExtraordinary shareholders meetingNasdaq first north growth marketEuropean headRare diseasesSmall capNasdaq stockholmமொபெர்க் பார்மாஒசிலோ பல்கலைக்கழகம்அசாதாரண பங்குதாரர்கள் சந்தித்தல்நாஸ்டாக் முதல் வடக்கு வளர்ச்சி சந்தை